SystImmune doses first patient in Phase III trial for ES-SCLC

Phase 3BL-M14D1atezolizumabPositive

AI Analysis

Summary

SystImmune has dosed the first patient in its Phase III BrenDeLL-Lung01 trial evaluating BL-M14D1 combined with atezolizumab for previously untreated extensive-stage small cell lung cancer. This milestone marks the initiation of the global clinical trial program.

Clinical Trial Data

Phase

Phase III

Outcome Details

First patient dosed in BrenDeLL-Lung01 trial

Importance:5/10

Sentiment:

0.30

Phase 3Clinical TrialOncologyES-SCLCFirst Patient Dosed

Related Companies

$GBCYD $TRAX $ARNA

Read the original article

Published by Clinical Trials Arena on August 6, 2026 9:04 AM

Read Original